INO: Immunotherapies Could Change the Future of Medicine

SAN FRANCISCO, CA--(Marketwired - Nov 4, 2013) - Patrick Cox, editor of the Transformational Technology Alert, stated in an interview with George Mack of The Life Sciences Report, "Inovio Pharmaceuticals Inc (NYSE MKT: INO) came out of the work of David Weiner, who is the father of DNA vaccines. Dr. Weiner discovered how to genetically engineer plasmids to produce any protein that is normally produced by our DNA. We can create artificial DNA with these plasmids to make things like antigens, which alert the immune system to the presence of disease when it's normally hidden, and then cause the immune system to ramp up production of specific kinds of T cells that will allow the effective countering of viral diseases or cancers. This is really an astonishing technology, and that's only the tip of the iceberg ... Inovio still has extraordinary potential. Monoclonal antibodies are expensive therapies, and they are difficult to handle, but Inovio's technology can actually produce monoclonal antibodies in these little inoculation sites. It puts this code in your body, and you make the antibodies yourself … I think that down the road, after Inovio's cancer and virus vaccines have begun to pay off and when the company is able to go where it wants to go, we're going to be looking at monoclonal antibodies, then life-extension technologies, and then other exciting applications.

Continue reading this interview with Patrick Cox: "This Biotechnology Platform Could Save Millions of Lives."

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.

DISCLOSURE:

The following companies mentioned in the interview are sponsors of The Life Sciences Report: Inovio Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Patrick Cox was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are his own and he is responsible for the content of the interview.